Condensed Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Net sales	$ 54,668,198	$ 44,483,740
Cost of sales	24,550,591	21,246,522
Gross profit	30,117,607	23,237,218
Operating expenses:
Research and development	1,967,666	907,170
Marketing	5,730,253	4,239,017
Selling, general, and administrative	17,637,681	11,237,303
Income (loss) from operations	4,782,007	6,853,728
Other (income) expense:
Interest expense (income), net	(30,157)	(282,645)
Guarantee fees	0	(138,864)
Change in fair value of warrant liability	(65,919)	(1,627,751)
Other income, net	57,855	0
Nonoperating Income (Expense), Total	(38,221)	(2,049,260)
Income (loss) before income taxes and loss from equity interests in unconsolidated affiliates	4,743,786	4,804,468
Income tax expense	32,545	40,530
Net income (loss) before loss from equity interests in unconsolidated affiliates	4,711,241	4,763,938
Loss from equity interests in unconsolidated affiliates	0	(57,448)
Net income	4,711,241	4,706,490
Net loss-non-controlling interests	(267,818)	0
Net income attributable to Thorne HealthTech, Inc.	4,979,059	4,706,490
Undistributed earnings attributable to Series E convertible preferred stockholders	0	(4,706,490)
Net income attributable to common stockholders	$ 4,979,059	$ 0
Earnings per share:
Basic	$ 0.09	$ 0
Diluted	$ 0.09	$ 0
Weighted average common shares outstanding:
Basic	52,564,779	17,650,035
Diluted	52,624,951	17,650,035